Right now, we’re witnessing a monumental shift in the world.
Artificial Intelligence is changing everything about the way people earn, spend, save, and invest their money.
The people who understand this stand to make an absolute mint!
It’s time to up your game… and jump straight in!
No matter whether you start with $50, $250, or $1,000…
Our No. 1 AI Pick is currently trading for pennies on the dollar compared to Nividia.
Nothing is guaranteed, but this is your chance to get in cheap and ride it to hundreds of dollars per share.
And here’s the great thing…
I’ll bet not one 1 in 10,000 investors knows about this scorching opportunity!
If you move quickly – before the mainstream press gets wind of what’s going on – this ”$3 AI Wonder Stock” could jumpstart the kind of carefree life you can only dream about right now.
But first, you’ll need to know its name and ticker symbol.
Which we’re prepared to give you now when you watch this video bulletin.
Your friends,
The Traders Agency Team
P.S. Grab your brand new 12-page Special Report called, The “$3 AI Wonder Stock” that Could Make You 75X Richer.
Full details are revealed in our special video presentation.
Tempus AI Hits $100—Are Shares Due for a Pullback?
Written by Leo Miller. Published 10/15/2025.
Key Points
- Tempus AI has been one of the most talked about names to IPO in the past few years.
- The stock briefly soared above $100 and is still up more than 150% from its initial price.
- What's driving the stock's recent gains, and should investors worry about a larger correction in this name?
Tempus AI (NASDAQ: TEM) has been publicly traded for only 16 months, and it has been a market standout over that time. Compared to its IPO price of $37, Tempus shares were roughly 155% higher on Monday, Oct. 13. The stock first eclipsed $100 on Oct. 8 and reached an intraday high of $104 on Oct. 9, before pulling back to close near $94 on Oct. 13.
Below, we'll review the recent developments behind Tempus AI's share-price move and, more importantly, analyze what the future may hold. Is the rally overdone, or do the fundamentals suggest further upside?
Device Clearances and Trump's AI Cancer Order Send Tempus Flying
This chart tells you what's next for America (Ad)
Elon Musk: "People will be talking about this moment in 100 years."
New documentary reveals how a terrifying force is about to trigger a generational transfer of wealth in America: potentially impoverishing millions while enriching a small group of others.
Prepare now or risk being left behind as this force reshapes everything about our economy, way of life, and finances.
Much of the recent strength in this healthcare stock reflects several key events. On Sept. 11, Tempus announced it received 510(k) clearance from the Food and Drug Administration (FDA) for its updated Tempus Pixel medical device. Pixel is an artificial intelligence (AI)-powered cardiac imaging platform that provides numerical data about the condition of different heart tissues. Tempus says this quantitative output can reveal issues that may be missed by visual inspection alone and can generate automated image reports, reducing the time clinicians spend on manual interpretation. Tempus shares jumped nearly 14% on the news.
The company also received 510(k) clearance for its Tempus xR IVD device on Sept. 22. That test analyzes cancerous tissue through RNA sequencing and is aimed at helping drug developers design better trials by identifying patients whose tumors are more likely to respond to specific treatments. While shares initially spiked on the announcement, they ultimately closed lower that day.
Finally, on Sept. 30, President Trump signed an executive order directing federal agencies to develop programs and increase investment in AI to fight pediatric cancer. The move aligns with Tempus's mission and opened the possibility of government-funded initiatives that could benefit the company. Tempus later confirmed on Oct. 9 that it was working with a U.S. government agency to support cancer research, although shares closed lower on that announcement as well.
Consensus Projects +20% Downside in TEM; Recent Targets Provide Some Solace
The MarketBeat-tracked consensus price target on Tempus sits just under $72, implying a potential downside of roughly 24% from current levels. Yet several recent analyst updates are more encouraging. HC Wainwright raised its forecast from $90 to $98 on Sept. 12, and Guggenheim lifted its price target from $80 to $95 on Sept. 26. Those revisions imply between essentially flat and about 4% upside versus the recent trading range.
While that upside is modest, the upgraded targets at least provide some justification for the stock's recent rally and suggest that certain analysts view the company's prospects more favorably than the broader consensus.
Multiple Factors Point to Tempus Being Overbought
Valuation is a concern. Tempus trades at a forward enterprise value to sales (EV/S) ratio of roughly 12x, well above the approximately 6x average forward EV/S for U.S. large-cap life sciences tools and services companies.
President Trump's executive order is a clear positive for the sector, but without a deeper understanding of the market opportunity for Tempus's newly cleared devices, it's difficult to quantify how much revenue they will generate. Importantly, 510(k) clearance means a device is considered "substantially equivalent" to an existing device; it does not necessarily indicate the product is superior or uniquely transformative. Tempus still must prove that these products will gain adoption and translate into meaningful revenue.
Taken together — the elevated valuation and relatively muted Wall Street forecasts — the evidence suggests the recent rally may be overextended. Over the long term, Tempus could still perform well given the company's relatively small revenues compared with overall pharma R&D spending (see analysis). For now, however, investors should approach the stock with caution and consider whether the current price adequately reflects execution risk and adoption timelines.
This email is a sponsored email for Traders Agency, a third-party advertiser of MarketBeat. Why was I sent this email message?.
This ad is sent on behalf of Traders Agency, LLC, at 20 N Orange Ave Suite 1100, Orlando, FL 32801. If you're not interested in this opportunity from Traders Agency, LLC.
If you need assistance with your subscription, feel free to email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103. U.S.A..